Dr Sussan Ghassabian

Associate Director at 360biolabs, a BioAgilytix company
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
AU

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Credentials

  • Technical Assessor Development Program
    National Association of Testing Authorities, Australia
    Sep, 2022
    - Nov, 2024
  • Leading and Managing the People Side of Technology and Manufacturing Teams in Bioscience Program
    BioMelbourne Network (Marlow Hampshire)
    May, 2021
    - Nov, 2024
  • Applied GCP Training for Investigational Sites and Sponsor Representatives E6(R2)
    ARCS Australia
    Sep, 2018
    - Nov, 2024
  • Neeli Higher Education Advanced Leadership Program (6-months on-line course)
    National Excellence in School Leadership Initiative
    Oct, 2016
    - Nov, 2024

Experience

  • 360biolabs, a BioAgilytix company
    • Australia
    • Biotechnology Research
    • 1 - 100 Employee
    • Associate Director
      • Oct 2021 - Present

      Managing studies and leading the Chemistry Team in Bioanalysis of the clinical and preclinical samples under GCP, GCLP, GLP and ISO17025. Managing studies and leading the Chemistry Team in Bioanalysis of the clinical and preclinical samples under GCP, GCLP, GLP and ISO17025.

  • Centre for Drug Candidate Optimisation
    • Monash University
    • Senior Research Officer
      • Jul 2019 - Oct 2021

      1. Supervision and leading of the bioanalytical team in method development and validation for novel compounds using LC-MS/MS 2. Planning and scheduling of the studies in coordination with other teams 3. PK evaluation of the preclinical data 1. Supervision and leading of the bioanalytical team in method development and validation for novel compounds using LC-MS/MS 2. Planning and scheduling of the studies in coordination with other teams 3. PK evaluation of the preclinical data

  • Therapeutic Goods Administration
    • Government Administration
    • 400 - 500 Employee
    • Senior Evaluator
      • Dec 2018 - Jun 2019

      Scientific Evaluation Branch, Medicines Regulation Division Scientific Evaluation Branch, Medicines Regulation Division

  • TetraQ RIC, Centre for Integrated Preclinical Drug Development
    • The University of Queensland
    • Research Fellow
      • Mar 2011 - Jun 2018

      1. LC-MS/MS method development and validation for novel compounds in clinical and preclinical Pharmacokinetic and Toxicology studies 2. In vitro drug metabolism studies of novel small molecules 3. In vivo Cytochrome P450 enzymes activity assessment (CYP Phenotyping) in patients. 1. LC-MS/MS method development and validation for novel compounds in clinical and preclinical Pharmacokinetic and Toxicology studies 2. In vitro drug metabolism studies of novel small molecules 3. In vivo Cytochrome P450 enzymes activity assessment (CYP Phenotyping) in patients.

  • University of Sydney
    • Australia
    • Higher Education
    • 700 & Above Employee
    • Postdoctoral Research Fellow
      • Aug 2009 - Dec 2010

      • LC-MS/MS method development and validation for measuring anticancer drug; sorafenib and its 5 metabolites in samples of human liver microsomes • In vitro metabolism of sorafenib using incubation with individual human liver microsomes, recombinant Cytochrome P450 (CYP) isoenzymes and CYP inhibition studies. • LC-MS/MS method development and validation for measuring anticancer drug; paclitaxel and its hydroxy metabolite in samples of human plasma • LC-MS/MS method development and validation for measuring anticancer drug; sorafenib and its 5 metabolites in samples of human liver microsomes • In vitro metabolism of sorafenib using incubation with individual human liver microsomes, recombinant Cytochrome P450 (CYP) isoenzymes and CYP inhibition studies. • LC-MS/MS method development and validation for measuring anticancer drug; paclitaxel and its hydroxy metabolite in samples of human plasma

  • Cosar Pharmaceutical Company
    • 1 - 100 Employee
    • Formulation Scientist / R&D
      • 2002 - 2004

      • Formulation of tablets, capsules and suspensions • Assessing formulations based on US and British Pharmacopeia including dissolution test • Using HPLC to implement US and British Pharmacopeia methods • Preparation of Drug Master File (DMF) for the formulated drugs. • Formulation of tablets, capsules and suspensions • Assessing formulations based on US and British Pharmacopeia including dissolution test • Using HPLC to implement US and British Pharmacopeia methods • Preparation of Drug Master File (DMF) for the formulated drugs.

  • Iran Daru Pharmaceutical Company
    • Tehran, Iran
    • Formulation Scientist / R&D
      • May 1999 - May 2002

      • Formulation of tablets, capsules, creams, gels and suspensions • Assessing formulations based on US and British Pharmacopeia including dissolution test • Using HPLC to implement US and British Pharmacopeia methods • Preparation of Drug Master File (DMF) for the formulated drugs. • Formulation of tablets, capsules, creams, gels and suspensions • Assessing formulations based on US and British Pharmacopeia including dissolution test • Using HPLC to implement US and British Pharmacopeia methods • Preparation of Drug Master File (DMF) for the formulated drugs.

Education

  • University of Sydney
    Doctor of Philosophy (PhD), Pharmacokinetics-Drug metabolism
    2005 - 2009
  • Shahid Beheshti University of Medical Sciences
    Doctor of Pharmacy (PharmD), Pharmacy

Community

You need to have a working account to view this content. Click here to join now